search
Back to results

Functional and Ultrasound Guided Resection of Glioblastoma (FUTURE-GB)

Primary Purpose

Glioma Glioblastoma Multiforme

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Standard of Care
Additional pre- and intra-operative imaging
Sponsored by
University of Oxford
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Glioma Glioblastoma Multiforme focused on measuring DTI, iUS

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18-70 years
  • Neuro-oncology Multi-Disciplinary Team (MDT) decision that the imaging shows a primary GB tumour which is maximally resectable (attempted gross total resection of all enhancing tumour)
  • Patient is suitable for concomitant adjuvant radiotherapy and Temozolomide (TMZ) chemotherapy or adjuvant TMZ at the time of MDT decision
  • Able to receive 5-ALA
  • Willing and able to give informed consent
  • Able to complete trial questionnaires, this may be with support where English is not their first language. (Stage 2 only)
  • Able to provide a proxy who is willing to complete questionnaires as requested (Stage 2 only).

Exclusion Criteria:

  • Midline/basal ganglia/cerebellum/brainstem GB
  • Multifocal GB
  • Recurrent GB
  • Suspected secondary GB
  • Contraindication to MRI

Sites / Locations

  • Queen Elizabeth Hospital, University Hospitals Birmingham NHSFT
  • Royal Sussex County Hospital
  • Southmead Hospital, North Bristol NHSTRecruiting
  • Addenbrookes Hospital, Cambridge University NHSFTRecruiting
  • University Hospital of Wales, Cardiff & Vale University Health BoardRecruiting
  • University Hospital, Coventry
  • Ninewells Hospital, NHS TaysideRecruiting
  • The Royal Infirmary of Edinburgh, NHS LothianRecruiting
  • Hull Royal InfirmaryRecruiting
  • Leeds General InfirmaryRecruiting
  • The Walton CentreRecruiting
  • Royal London Hospital, Barts Health NHS TrustRecruiting
  • King's College HospitalRecruiting
  • Charing Cross Hospital/St Mary's, Imperial College Healthcare NHS TrustRecruiting
  • James Cook University Hospital, South Tees Hospitals NHSFTRecruiting
  • Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHSFT
  • Queen's Medical Centre, Nottingham University Hospitals NHSTRecruiting
  • The John Radcliffe Hospital, Oxford University Hospitals NHSFTRecruiting
  • Derriford Hospital, University Hospitals Plymouth NHS TrustRecruiting
  • Royal Preston Hospital, Lancashire Teaching Hospitals NHSFT
  • Queen's Hospital, Barking, Havering and Redbridge University Hospitals NHST
  • Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust
  • Southampton General Hospital, University Hospital Southampton NHSFTRecruiting
  • Royal Stoke University Hospital, University Hospitals of North Midlands NHSTRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Additional pre- and intra-operative imaging

Standard of Care

Arm Description

Surgery to resect the GB using Diffusion Tensor Imaging (DTI) and intraoperative Ultrasound (iUS) (navigated iUS where available) in addition to standard care (i.e. neuronavigation based on preoperative MRI and intraoperative use of 5-aminolevulinic acid (5-ALA))

The comparator is standard care as per current NICE guidelines (i.e. neuronavigation based on preoperative MRI and intraoperative use of 5-ALA).

Outcomes

Primary Outcome Measures

Stage 1 Primary Outcome: to demonstrate the feasibility of using DTI and iUS in addition to standard of care for neurosurgery using a combination of qualitative and quantitative data to prove workflow capability at each site.
Sites are qualitatively assessed through a standardisation stage, providing feedback to enable learning and ensure the workflow is followed. Sites with satisfactory data will "progress" and pass into Stage 2. The measures assessed in combination are: Operation length, in normal range for this surgery. Use of DTI neuronavigation & iUS to achieve maximal safe tumour resection without major neurological deficit, measured by getting clear, relevant images for the DTI & US scans, and accurate pre-operative tractography. Extent of tumour resection (cm³ remaining) on postoperative MRI scan. Surgical Complications/Serious Adverse Events-measured from recorded post-operative complications and a 6-month notes check to ensure patient safety. If the assessment panel is satisfied with the data after ~3 recruits, a site will progress into Stage 2 of the trial, the RCT. Data will be analysed for Stage 1 once all sites have progressed through into Stage 2 of the trial.
Stage 2 Primary Outcome: to assess whether additional imaging to standard of care changes Deterioration Free Survival (DFS) (Where deterioration relates to global health status only)
This is measured by a composite of: Change in global health status domain of the QLQ-C30 questionnaire (Quality of Life Questionnaire Cancer) from baseline to final questionnaire completion. Questionnaires are administered at baseline, 6 weeks, then every 3 months until 24months. Progression Free Survival (PFS). This is measured by radiological tumour progression on imaging, which is taken 3-months post-op and 3-monthly thereafter. Overall Survival (OS) with an event defined as either deterioration, progression or death.

Secondary Outcome Measures

Stage 2: To assess if additional intraoperative imaging changes DFS where deterioration relates to physical and social functioning, and motor and communication dysfunction
This is measured using a combination of specific questions (physical functioning and social functioning) in the QLQ-C30 (Quality of Life Questionnaire Cancer) and BN20 questionnaire (Quality of Life Questionnaire Brain) (motor dysfunction and communication deficit questions), combined with the values of Progression Free Survival (PFS) and overall survival (OS) taken from the primary outcome. Questionnaires are administered at baseline, 6 weeks, then every 3 months until 24months.
Stage 2: To assess whether additional intraoperative imaging to standard of care changes time to deterioration
Defined similar to DFS with the exception that progression is excluded as an event (i.e. only deterioration or death are considered). There will be five time to deterioration outcomes, one for each of the domains utilised in the primary and secondary DFS outcomes, used in turn to define deterioration
Stage 2: To assess whether additional intraoperative imaging to standard of care improves Overall Survival (OS)
OS (time from randomisation to death or trial closure)
Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes Progression Free Survival (PFS)
PFS (time from randomisation to radiological tumour progression on imaging, as agreed in local MDT This involves using the post-operative MRI scan as a reference point and making comparisons will the ensuing MRI reports that are recieved 3 months post-surgery and 3 monthly thereafter until 24 months post-surgery.
Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes the extent of tumour resection
Extent of resection as percent of pre-operative tumour volume on postoperative contrast enhanced MRI
Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes the incidence of surgical complications
Number and type of surgical complications
Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes the number of patients eligible for adjuvant treatment following surgery
Number of patients eligible for adjuvant treatment
Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes functional outcome postoperatively
Measured by any change in the functional performance assessment which consistes of a combination of: The WHO (World Health Organisation) performance status A 5-minute telephone mini-MoCA (The Montreal Cognitive Assessment, Montreal Version) Barthel Index MRC (Medical Research Council) grading of power in all 4 limbs Assessments are made at baseline, at hospital discharge, 6 weeks post-op, 3 months post-op, then 3 monthly thereafter until 24 months.
Stage 2: Assess the correlation of proxy to participant classification assessment of quality of life
Assessed using comparisons between the patient and proxy responses to the Quality of Life questionnaires administered. Specifically comparisons between the answers to questions 29 and 30 of the QLQ-C30.

Full Information

First Posted
November 24, 2021
Last Updated
May 26, 2022
Sponsor
University of Oxford
Collaborators
Imperial College Healthcare NHS Trust, Efficacy and Mechanism Evaluation (EME) Programme
search

1. Study Identification

Unique Protocol Identification Number
NCT05399524
Brief Title
Functional and Ultrasound Guided Resection of Glioblastoma
Acronym
FUTURE-GB
Official Title
FUTURE-GB Trial (Functional and Ultrasound-guided Resection of Glioblastoma) A 2-Stage Trial. A Learning Phase Evaluation of Participating Centres, Followed by a Randomised, Controlled Multicentre Phase III Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2020 (Actual)
Primary Completion Date
October 2025 (Anticipated)
Study Completion Date
November 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Oxford
Collaborators
Imperial College Healthcare NHS Trust, Efficacy and Mechanism Evaluation (EME) Programme

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Functional and ultrasound-guided resection of glioblastoma: assessing the use of additional imaging during surgery to improve outcomes for patients with glioblastoma brain tumours
Detailed Description
Stage 1 (IDEAL IIB study) of the trial is observational only and all participants will receive all technologies during surgery. Stage 2 will be randomised. Randomisation will be via the web-based service provided by the Oxford Clinical Trials Research Unit (OCTRU), using the method of minimisation. Participants will be randomised 1:1 to either: Standard care surgery (neuronavigation based on preoperative imaging and intraoperative use of 5-ALA)(Control arm) Standard care surgery (neuronavigation based on preoperative imaging and intraoperative use of 5-ALA) AND of DTI neuronavigation and NiUS (Intervention arm) At baseline all participants will undergo a routine preoperative neuronavigation MRI scan. Those participants randomised to the experimental arm, will also have a DTI scan (additional 5 minutes in the MRI). All participants will then undergo the planned resection of their tumour, with the additional technologies if they are in the experimental arm. Following surgery, participants in both arms have the same follow up schedule and undergo standard clinical care for a total of 24 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glioma Glioblastoma Multiforme
Keywords
DTI, iUS

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
FUTURE-GB is a 2-Stage trial: Stage 1 is a non-randomised multicentre learning and evaluation Stage (IDEAL IIB study), and Stage 2 a prospective, multicentre definitive randomised controlled trial.
Masking
ParticipantOutcomes Assessor
Masking Description
Participants are blinded
Allocation
Randomized
Enrollment
357 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Additional pre- and intra-operative imaging
Arm Type
Experimental
Arm Description
Surgery to resect the GB using Diffusion Tensor Imaging (DTI) and intraoperative Ultrasound (iUS) (navigated iUS where available) in addition to standard care (i.e. neuronavigation based on preoperative MRI and intraoperative use of 5-aminolevulinic acid (5-ALA))
Arm Title
Standard of Care
Arm Type
Active Comparator
Arm Description
The comparator is standard care as per current NICE guidelines (i.e. neuronavigation based on preoperative MRI and intraoperative use of 5-ALA).
Intervention Type
Other
Intervention Name(s)
Standard of Care
Intervention Description
Neuronavigation and intraoperative 5-ALA
Intervention Type
Other
Intervention Name(s)
Additional pre- and intra-operative imaging
Other Intervention Name(s)
DTI, IUS
Intervention Description
Additional DTI scan during routine pre-operative tumour MRI scan, additional use of intraoperative ultrasound in addition to normal to standard of care (Neuronavigation and intraoperative 5-ALA)
Primary Outcome Measure Information:
Title
Stage 1 Primary Outcome: to demonstrate the feasibility of using DTI and iUS in addition to standard of care for neurosurgery using a combination of qualitative and quantitative data to prove workflow capability at each site.
Description
Sites are qualitatively assessed through a standardisation stage, providing feedback to enable learning and ensure the workflow is followed. Sites with satisfactory data will "progress" and pass into Stage 2. The measures assessed in combination are: Operation length, in normal range for this surgery. Use of DTI neuronavigation & iUS to achieve maximal safe tumour resection without major neurological deficit, measured by getting clear, relevant images for the DTI & US scans, and accurate pre-operative tractography. Extent of tumour resection (cm³ remaining) on postoperative MRI scan. Surgical Complications/Serious Adverse Events-measured from recorded post-operative complications and a 6-month notes check to ensure patient safety. If the assessment panel is satisfied with the data after ~3 recruits, a site will progress into Stage 2 of the trial, the RCT. Data will be analysed for Stage 1 once all sites have progressed through into Stage 2 of the trial.
Time Frame
Measured 6 weeks post-surgery
Title
Stage 2 Primary Outcome: to assess whether additional imaging to standard of care changes Deterioration Free Survival (DFS) (Where deterioration relates to global health status only)
Description
This is measured by a composite of: Change in global health status domain of the QLQ-C30 questionnaire (Quality of Life Questionnaire Cancer) from baseline to final questionnaire completion. Questionnaires are administered at baseline, 6 weeks, then every 3 months until 24months. Progression Free Survival (PFS). This is measured by radiological tumour progression on imaging, which is taken 3-months post-op and 3-monthly thereafter. Overall Survival (OS) with an event defined as either deterioration, progression or death.
Time Frame
Measured from baseline up to 24 months
Secondary Outcome Measure Information:
Title
Stage 2: To assess if additional intraoperative imaging changes DFS where deterioration relates to physical and social functioning, and motor and communication dysfunction
Description
This is measured using a combination of specific questions (physical functioning and social functioning) in the QLQ-C30 (Quality of Life Questionnaire Cancer) and BN20 questionnaire (Quality of Life Questionnaire Brain) (motor dysfunction and communication deficit questions), combined with the values of Progression Free Survival (PFS) and overall survival (OS) taken from the primary outcome. Questionnaires are administered at baseline, 6 weeks, then every 3 months until 24months.
Time Frame
Measured from baseline up to 24 months
Title
Stage 2: To assess whether additional intraoperative imaging to standard of care changes time to deterioration
Description
Defined similar to DFS with the exception that progression is excluded as an event (i.e. only deterioration or death are considered). There will be five time to deterioration outcomes, one for each of the domains utilised in the primary and secondary DFS outcomes, used in turn to define deterioration
Time Frame
Measured from baseline up to 24 months
Title
Stage 2: To assess whether additional intraoperative imaging to standard of care improves Overall Survival (OS)
Description
OS (time from randomisation to death or trial closure)
Time Frame
To be recorded at 24 months
Title
Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes Progression Free Survival (PFS)
Description
PFS (time from randomisation to radiological tumour progression on imaging, as agreed in local MDT This involves using the post-operative MRI scan as a reference point and making comparisons will the ensuing MRI reports that are recieved 3 months post-surgery and 3 monthly thereafter until 24 months post-surgery.
Time Frame
MRI at 6 months post-op., and then 3 monthly up to 24 months or an MRI performed outside protocol if patient is symptomatic
Title
Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes the extent of tumour resection
Description
Extent of resection as percent of pre-operative tumour volume on postoperative contrast enhanced MRI
Time Frame
Measured 1 week post-surgery
Title
Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes the incidence of surgical complications
Description
Number and type of surgical complications
Time Frame
Measured from surgery up to 24 months
Title
Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes the number of patients eligible for adjuvant treatment following surgery
Description
Number of patients eligible for adjuvant treatment
Time Frame
Measured 3 months post surgery
Title
Stage 2: To assess whether additional intraoperative imaging (DTI and iUS*) to standard of care (Neuronavigation and intraoperative 5-ALA) changes functional outcome postoperatively
Description
Measured by any change in the functional performance assessment which consistes of a combination of: The WHO (World Health Organisation) performance status A 5-minute telephone mini-MoCA (The Montreal Cognitive Assessment, Montreal Version) Barthel Index MRC (Medical Research Council) grading of power in all 4 limbs Assessments are made at baseline, at hospital discharge, 6 weeks post-op, 3 months post-op, then 3 monthly thereafter until 24 months.
Time Frame
Measured from baseline up to 24 months
Title
Stage 2: Assess the correlation of proxy to participant classification assessment of quality of life
Description
Assessed using comparisons between the patient and proxy responses to the Quality of Life questionnaires administered. Specifically comparisons between the answers to questions 29 and 30 of the QLQ-C30.
Time Frame
Measured from baseline up to 24 months. Proxy will not complete questionnaires when participant stops completing them.
Other Pre-specified Outcome Measures:
Title
Tertiary Mechanistic Objectives (on a sub set of participants): assessment of the sensitivity and specificity of the anatomico-spatial location of DTI fibre tracts compared to Standard of Care
Description
To assess the sensitivity and specificity of the anatomico-spatial location of DTI fibre tracts compared with intraoperative direct electrical stimulation/behavioural change without stimulation but related to adjacent white fibre tract in patients undergoing awake surgery, or motor evoked potential changes in patients undergoing surgery. Measured by sensitivity and specificity calculation using pre and post-surgery MRI images
Time Frame
6 weeks post-surgery
Title
Tertiary Mechanistic Objectives (on a sub set of participants): assessment of the sensitivity and specificity of iUS to identify the tumour boundary when compared with 5-ALA.
Description
To assess the sensitivity and specificity of iUS* to identify the tumour boundary when compared with 5-ALA, navigated biopsies will be taken from tumour boundary tissue planned for resection. Intra operative iUS* images and post-operative MRI scans and Intraoperative biopsy samples
Time Frame
6 weeks post-surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-70 years Neuro-oncology Multi-Disciplinary Team (MDT) decision that the imaging shows a primary GB tumour which is maximally resectable (attempted gross total resection of all enhancing tumour) Patient is suitable for concomitant adjuvant radiotherapy and Temozolomide (TMZ) chemotherapy or adjuvant TMZ at the time of MDT decision Able to receive 5-ALA Willing and able to give informed consent Able to complete trial questionnaires, this may be with support where English is not their first language. (Stage 2 only) Able to provide a proxy who is willing to complete questionnaires as requested (Stage 2 only). Exclusion Criteria: Midline/basal ganglia/cerebellum/brainstem GB Multifocal GB Recurrent GB Suspected secondary GB Contraindication to MRI
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amy Taylor
Phone
44 7917 101 649
Email
futuregb@nds.ox.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Puneet Plaha
Organizational Affiliation
University of Oxford
Official's Role
Study Director
Facility Information:
Facility Name
Queen Elizabeth Hospital, University Hospitals Birmingham NHSFT
City
Birmingham
ZIP/Postal Code
B15 2TH
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Colin Watts
Email
c.watts.2@bham.ac.uk
Facility Name
Royal Sussex County Hospital
City
Brighton
ZIP/Postal Code
BN2 5BE
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giles Critchley
Email
giles.critchley@nhs.net
Facility Name
Southmead Hospital, North Bristol NHST
City
Bristol
ZIP/Postal Code
BS10 5NB
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Neil Barua
Email
neilbarua@doctors.org.uk
Facility Name
Addenbrookes Hospital, Cambridge University NHSFT
City
Cambridge
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephen Price
Email
sjp58@cam.ac.uk
Facility Name
University Hospital of Wales, Cardiff & Vale University Health Board
City
Cardiff
ZIP/Postal Code
CF14 4XW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
George Eralil
Email
george.eralil@wales.nhs.uk
Facility Name
University Hospital, Coventry
City
Coventry
ZIP/Postal Code
CV2 2DX
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sandeep Solanki
Email
Sandeep.Solanki@uhcw.nhs.uk
Facility Name
Ninewells Hospital, NHS Tayside
City
Dundee
ZIP/Postal Code
DD2 1SG
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Solth
Email
anna.solth1@nhs.scot
Facility Name
The Royal Infirmary of Edinburgh, NHS Lothian
City
Edinburgh
ZIP/Postal Code
EH16
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul Brennan
Email
paul.brennan@ed.ac.uk
Facility Name
Hull Royal Infirmary
City
Hull
ZIP/Postal Code
HU3 2JZ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chittoor Rajaraman
Email
chittoor.rajaraman@nhs.net
Facility Name
Leeds General Infirmary
City
Leeds
ZIP/Postal Code
LS1 3EX
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robert Corns
Email
robertcorns@nhs.net
Facility Name
The Walton Centre
City
Liverpool
ZIP/Postal Code
L9 7LJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Jenkinson
Email
Michael.Jenkinson@liverpool.ac.uk
Facility Name
Royal London Hospital, Barts Health NHS Trust
City
London
ZIP/Postal Code
E1 1BB
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Edward McKintosh
Email
edward.mckintosh@nhs.net
Facility Name
King's College Hospital
City
London
ZIP/Postal Code
SE5 9RS
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Keyoumars Ashkan
Email
k.ashkan@nhs.net
Facility Name
Charing Cross Hospital/St Mary's, Imperial College Healthcare NHS Trust
City
London
ZIP/Postal Code
W6 8RF
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophie Camp
Email
sophie.camp@nhs.net
First Name & Middle Initial & Last Name & Degree
Dipankar Nandi
Email
dipankar.nandi@nhs.net
Facility Name
James Cook University Hospital, South Tees Hospitals NHSFT
City
Middlesbrough
ZIP/Postal Code
TS4 3BW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anil Varma
Email
anil.varma@nhs.net
Facility Name
Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHSFT
City
Newcastle Upon Tyne
ZIP/Postal Code
NE1 4LP
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Damian Holliman
Email
damian.holliman@nhs.net
Facility Name
Queen's Medical Centre, Nottingham University Hospitals NHST
City
Nottingham
ZIP/Postal Code
NG7 2UH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stuart Smith
Email
stuart.smith@nottingham.ac.uk
Facility Name
The John Radcliffe Hospital, Oxford University Hospitals NHSFT
City
Oxford
ZIP/Postal Code
OX3 9DU
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Puneet Plaha
Email
Puneet.plaha@ouh.nhs.uk
Facility Name
Derriford Hospital, University Hospitals Plymouth NHS Trust
City
Plymouth
ZIP/Postal Code
PL6 8DH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
James Palmer
Email
jamespalmer1@nhs.net
Facility Name
Royal Preston Hospital, Lancashire Teaching Hospitals NHSFT
City
Preston
ZIP/Postal Code
PR2 9HT
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isaac Phang
Email
Isaac.Phang@LTHTR.nhs.uk
Facility Name
Queen's Hospital, Barking, Havering and Redbridge University Hospitals NHST
City
Romford
ZIP/Postal Code
RM7 0AG
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nik Haliasos
Email
n.haliasos@nhs.net
Facility Name
Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust
City
Sheffield
ZIP/Postal Code
S10 2JF
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yahia Al-Tamimi
Email
yahia.al-tamimi@nhs.net
Facility Name
Southampton General Hospital, University Hospital Southampton NHSFT
City
Southampton
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul Grundy
Email
paul.grundy@nhs.net
Facility Name
Royal Stoke University Hospital, University Hospitals of North Midlands NHST
City
Stoke-on-Trent
ZIP/Postal Code
ST4 6QG
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erminia Albanese
Email
Erminia.Albanese@uhnm.nhs.uk

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Functional and Ultrasound Guided Resection of Glioblastoma

We'll reach out to this number within 24 hrs